Advertisement
Screener

OMEROS CORP (OMER) Comprehensive Income

2.8 / 5 stars · 68/120 Roast Me

OMEROS CORP Comprehensive Income

OMEROS CORP (OMER) reported Comprehensive Income of -$22.70 million for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-09.

Discontinued › Income Statement › Unrealized Gains

us-gaap:ComprehensiveIncomeNetOfTax · last filed 2021-11-09

  • OMEROS CORP comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2021-09-30 was -$22.70M.
  • OMEROS CORP comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2021-06-30 was -$28.59M.
  • OMEROS CORP comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2021-03-31 was -$35.09M.
  • OMEROS CORP comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2020-12-31 was -$37.27M.
  • OMEROS CORP comprehensive income (loss), net of tax, attributable to parent for fiscal 2020 was -$138.06M.
  • OMEROS CORP comprehensive income (loss), net of tax, attributable to parent for fiscal 2019 was -$84.49M.
  • OMEROS CORP comprehensive income (loss), net of tax, attributable to parent for fiscal 2018 was -$126.76M.
  • OMEROS CORP comprehensive income (loss), net of tax, attributable to parent for fiscal 2017 was -$53.48M.
Period endComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 6 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 9 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month
2021-09-30-$22.70M
10-Q · filed 2021-11-09
-$51.30M
derived: sum of 2 quarters · filed 2021-11-09
-$86.39M
10-Q · filed 2021-11-09
-$123.66M
derived: sum of 4 quarters · filed 2021-11-09
2021-06-30-$28.59M
10-Q · filed 2021-08-09
-$63.68M
10-Q · filed 2021-08-09
-$100.96M
derived: sum of 3 quarters · filed 2021-08-09
-$139.42M
derived: sum of 4 quarters · filed 2021-11-09
2021-03-31-$35.09M
10-Q · filed 2021-05-10
-$72.36M
derived: sum of 2 quarters · filed 2021-05-10
-$110.83M
derived: sum of 3 quarters · filed 2021-11-09
-$144.12M
derived: sum of 4 quarters · filed 2021-11-09
2020-12-31-$37.27M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01
-$75.74M
derived: sum of 2 quarters · filed 2021-11-09
-$109.03M
derived: sum of 3 quarters · filed 2021-11-09
-$138.06M
10-K · filed 2021-03-01
2020-09-30-$38.46M
10-Q · filed 2021-11-09
-$71.76M
derived: sum of 2 quarters · filed 2021-11-09
-$100.79M
10-Q · filed 2021-11-09
-$130.01M
derived: sum of 4 quarters · filed 2021-11-09
2020-06-30-$33.29M
10-Q · filed 2021-08-09
-$62.33M
10-Q · filed 2021-08-09
-$91.55M
derived: sum of 3 quarters · filed 2021-08-09
-$108.01M
derived: sum of 4 quarters · filed 2021-08-09
2020-03-31-$29.03M
10-Q · filed 2021-05-10
-$58.26M
derived: sum of 2 quarters · filed 2021-05-10
-$74.72M
derived: sum of 3 quarters · filed 2021-05-10
-$89.17M
derived: sum of 4 quarters · filed 2021-05-10
2019-12-31-$29.23M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01
-$45.69M
derived: sum of 2 quarters · filed 2021-03-01
-$60.14M
derived: sum of 3 quarters · filed 2021-03-01
-$84.49M
10-K · filed 2021-03-01
2019-09-30-$16.46M
10-Q · filed 2020-11-09
-$30.92M
derived: sum of 2 quarters · filed 2020-11-09
-$55.26M
10-Q · filed 2020-11-09
-$78.80M
derived: sum of 4 quarters · filed 2021-03-01
2019-06-30-$14.45M
10-Q · filed 2020-08-10
-$38.80M
10-Q · filed 2020-08-10
-$62.33M
derived: sum of 3 quarters · filed 2021-03-01
-$101.80M
derived: sum of 4 quarters · filed 2021-03-01
2019-03-31-$24.34M
10-Q · filed 2020-05-11
-$47.88M
derived: sum of 2 quarters · filed 2021-03-01
-$87.35M
derived: sum of 3 quarters · filed 2021-03-01
-$121.05M
derived: sum of 4 quarters · filed 2021-03-01
2018-12-31-$23.53M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01
-$63.01M
derived: sum of 2 quarters · filed 2021-03-01
-$96.70M
derived: sum of 3 quarters · filed 2021-03-01
-$126.76M
10-K · filed 2021-03-01
2018-09-30-$39.47M
10-Q · filed 2019-11-12
-$73.17M
derived: sum of 2 quarters · filed 2019-11-12
-$103.22M
10-Q · filed 2019-11-12
-$119.77M
derived: sum of 4 quarters · filed 2020-03-02
2018-06-30-$33.70M
10-Q · filed 2019-08-08
-$63.75M
10-Q · filed 2019-08-08
-$80.30M
derived: sum of 3 quarters · filed 2020-03-02
-$87.78M
derived: sum of 4 quarters · filed 2020-03-02
2018-03-31-$30.05M
10-Q · filed 2019-05-09
-$46.60M
derived: sum of 2 quarters · filed 2020-03-02
-$54.09M
derived: sum of 3 quarters · filed 2020-03-02
-$68.45M
derived: sum of 4 quarters · filed 2020-03-02
2017-12-31-$16.55M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02
-$24.03M
derived: sum of 2 quarters · filed 2020-03-02
-$38.39M
derived: sum of 3 quarters · filed 2020-03-02
-$53.48M
10-K · filed 2020-03-02
2017-09-30-$7.48M
10-Q · filed 2018-11-08
-$21.84M
derived: sum of 2 quarters · filed 2018-11-08
-$36.93M
10-Q · filed 2018-11-08
-$56.56M
derived: sum of 4 quarters · filed 2019-03-01
2017-06-30-$14.36M
10-Q · filed 2018-08-09
-$29.45M
10-Q · filed 2018-08-09
-$49.08M
derived: sum of 3 quarters · filed 2019-03-01
-$63.04M
derived: sum of 4 quarters · filed 2019-03-01
2017-03-31-$15.09M
10-Q · filed 2018-05-10
-$34.72M
derived: sum of 2 quarters · filed 2019-03-01
-$48.68M
derived: sum of 3 quarters · filed 2019-03-01
-$61.30M
derived: sum of 4 quarters · filed 2019-03-01
2016-12-31-$19.63M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01
-$33.59M
derived: sum of 2 quarters · filed 2019-03-01
-$46.21M
derived: sum of 3 quarters · filed 2019-03-01
-$66.75M
10-K · filed 2019-03-01
2016-09-30-$13.96M
10-Q · filed 2017-11-09
-$26.57M
derived: sum of 2 quarters · filed 2017-11-09
-$47.11M
10-Q · filed 2017-11-09
-$66.94M
derived: sum of 4 quarters · filed 2018-03-01
2016-06-30-$12.61M
10-Q · filed 2017-08-08
-$33.15M
10-Q · filed 2017-08-08
-$52.98M
derived: sum of 3 quarters · filed 2018-03-01
-$72.90M
derived: sum of 4 quarters · filed 2018-03-01
2016-03-31-$20.54M
10-Q · filed 2017-05-10
-$40.37M
derived: sum of 2 quarters · filed 2018-03-01
-$60.29M
derived: sum of 3 quarters · filed 2018-03-01
-$76.97M
derived: sum of 4 quarters · filed 2018-03-01
2015-12-31-$19.83M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01
-$39.75M
derived: sum of 2 quarters · filed 2018-03-01
-$56.43M
derived: sum of 3 quarters · filed 2018-03-01
-$75.10M
10-K · filed 2018-03-01
2015-09-30-$19.92M
10-Q · filed 2016-11-09
-$36.60M
derived: sum of 2 quarters · filed 2016-11-09
-$55.27M
10-Q · filed 2016-11-09
-$75.98M
derived: sum of 4 quarters · filed 2017-03-16
2015-06-30-$16.68M
10-Q · filed 2016-08-09
-$35.35M
10-Q · filed 2016-08-09
-$56.06M
derived: sum of 3 quarters · filed 2017-03-16
-$74.39M
derived: sum of 4 quarters · filed 2017-03-16
2015-03-31-$18.67M
10-Q · filed 2016-05-10
-$39.38M
derived: sum of 2 quarters · filed 2017-03-16
-$57.71M
derived: sum of 3 quarters · filed 2017-03-16
-$75.70M
derived: sum of 4 quarters · filed 2017-03-16
2014-12-31-$20.71M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16
-$39.04M
derived: sum of 2 quarters · filed 2017-03-16
-$57.03M
derived: sum of 3 quarters · filed 2017-03-16
-$73.67M
10-K · filed 2017-03-16
2014-09-30-$18.33M
10-Q · filed 2015-11-09
-$36.32M
derived: sum of 2 quarters · filed 2015-11-09
-$52.96M
10-Q · filed 2015-11-09
-$54.80M
derived: sum of 4 quarters · filed 2016-03-15
2014-06-30-$17.99M
10-Q · filed 2015-08-10
-$34.63M
10-Q · filed 2015-08-10
-$36.48M
derived: sum of 3 quarters · filed 2016-03-15
-$50.35M
derived: sum of 4 quarters · filed 2016-03-15
2014-03-31-$16.64M
10-Q · filed 2015-05-11
-$18.49M
derived: sum of 2 quarters · filed 2016-03-15
-$32.36M
derived: sum of 3 quarters · filed 2016-03-15
-$45.95M
derived: sum of 4 quarters · filed 2016-03-15
2013-12-31-$1.84M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15
-$15.71M
derived: sum of 2 quarters · filed 2016-03-15
-$29.31M
derived: sum of 3 quarters · filed 2016-03-15
-$39.80M
10-K · filed 2016-03-15
2013-09-30-$13.87M
10-Q · filed 2014-11-10
-$27.46M
derived: sum of 2 quarters · filed 2014-11-10
-$37.95M
10-Q · filed 2014-11-10
-$45.69M
derived: sum of 4 quarters · filed 2015-03-16
2013-06-30-$13.59M
10-Q · filed 2014-08-11
-$24.08M
10-Q · filed 2014-08-11
-$31.82M
derived: sum of 3 quarters · filed 2015-03-16
-$45.09M
derived: sum of 4 quarters · filed 2015-03-16
2013-03-31-$10.49M
10-Q · filed 2014-05-12
-$18.22M
derived: sum of 2 quarters · filed 2015-03-16
-$31.50M
derived: sum of 3 quarters · filed 2015-03-16
-$40.04M
derived: sum of 4 quarters · filed 2015-03-16
2012-12-31-$7.73M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16
-$21.01M
derived: sum of 2 quarters · filed 2015-03-16
-$29.55M
derived: sum of 3 quarters · filed 2015-03-16
-$38.44M
10-K · filed 2015-03-16
2012-09-30-$13.28M
10-Q · filed 2013-11-07
-$21.82M
derived: sum of 2 quarters · filed 2013-11-07
-$30.71M
10-Q · filed 2013-11-07
-$40.91M
derived: sum of 4 quarters · filed 2014-03-13
2012-06-30-$8.54M
10-Q · filed 2013-08-09
-$17.43M
10-Q · filed 2013-08-09
-$27.64M
derived: sum of 3 quarters · filed 2014-03-13
-$34.15M
derived: sum of 4 quarters · filed 2014-03-13
2012-03-31-$8.89M
10-Q · filed 2013-05-09
-$19.10M
derived: sum of 2 quarters · filed 2014-03-13
-$25.61M
derived: sum of 3 quarters · filed 2014-03-13
-$30.90M
derived: sum of 4 quarters · filed 2014-03-13
2011-12-31-$10.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-13
-$16.71M
derived: sum of 2 quarters · filed 2014-03-13
-$22.00M
derived: sum of 3 quarters · filed 2014-03-13
-$28.55M
10-K · filed 2014-03-13
2011-09-30-$6.51M
10-Q · filed 2012-11-09
-$11.80M
derived: sum of 2 quarters · filed 2012-11-09
-$18.34M
10-Q · filed 2012-11-09
2011-06-30-$5.29M
10-Q · filed 2012-08-07
-$11.83M
10-Q · filed 2012-08-07
2011-03-31-$6.54M
10-Q · filed 2012-05-10
2010-12-31-$29.29M
10-K · filed 2013-03-18
2009-12-31-$20.95M
10-K · filed 2012-03-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Ultragenyx Pharmaceutical Inc. (RARE)United States$1.456B-5.62
ArriVent BioPharma, Inc. (AVBP)United States$1.485B-10.25
Innoviva, Inc. (INVA)United States$1.493B4.62
Oric Pharmaceuticals, Inc. (ORIC)United States$1.367B-8.00
ANAPTYSBIO, INC (ANAB)United States$1.546B-60.20
Kailera Therapeutics, Inc. (KLRA)United States$1.552B
Kardigan, Inc. (KARD)United States$1.346B
Tyra Biosciences, Inc. (TYRA)United States$1.337B-12.83
Bicara Therapeutics Inc. (BCAX)United States$1.309B-10.55
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82